Close Menu

NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a filing made yesterday with the US Securities and Exchange Commission.

Biocept received a notice from Nasdaq stating that it had failed to maintain a required minimum closing bid price of at least $1 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.